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Liver Transplantation in Hemophilia A 
By Franklin A. Bontempo, Jessica H. Lewis, Toni J. Gorenc, Joel A. Spero, Margaret V. Ragni, 
J.P. Scott, and Thomas E. Starzl 
Four patients with hemophilia A have undergone liver 
transplantation in our institution. three successfully. The 
first was a 21-year-old man with chronic active hepatitis 
(CAH) in whom the effects of previous abdominal opera-
tions prevented the satisfactory technical insertion of the 
new liver. He died intraoperatively. The second patient was 
a 15-year-old boy with CAH who began to synthesize factor 
VIII coagulant activity (F VIII:C) within 18 hours of success-
ful liver transplantation and has continued to do so for 
almost 2 years (F VIII:C range 0.89 to 3.20 U/mL). The first 
2 months of his postoperative course were complicated by 
infections. but since that time he has done well and has 
returned to school. The third patient was a 48-year-old 
man with portal fibrosis and severe ascites. He synthesized 
W HILE the site of production of human factor VIII 
coagulant activity (F VIII:C) has been unclear, data 
generated during the past two decades have consistently 
implicated the liver as the primary site of synthesis. This was 
accomplished utilizing liver perfusion techniques!·3 and 
orthotopic hepatic transplantation into hemophiliac dogs.4 
However, others have suggested that the spleen5.7 or lungS 
were important as well. Recent immunohistologic advances 
have localized F VIII:C primarily to the liver9• IO and in 
particular to hepatic sinusoidal cells.IO Whether these cells 
are the site of synthesis or are merely serving a storage 
function is not known. By recombinant DNA techniques,1l-!4 
F VIII:C messenger RNA has been demonstrated in the 
hepatocyte!4 as well as the kidney, although the latter was 
not identified as a site of origin. 15 The first successful human 
orthotopic liver transplantation in a F VIII-deficient hemo-
philiac was recently reported in a letter from this labora-
tory.16 The new liver reversed the F VIII:C defect. The 
purpose of this report is to describe in detail the orthotopic 
liver transplantation in four F VIII:C-deficient hemophil-
iacs. All patients were advised of procedures and attendant 
risks, in accordance with institutional guidelines, and gave 
informed consent. In the three who survived the surgery, F 
Vlll:C levels normalized, and their bleeding problems 
resolved. 
CASE PRESENTATIONS 
Patient I was a 21-year-old white, moderately F VIII:C-deficient 
hemophiliac who had received multiple infusions of F VIn concen-
trate in the past and had developed severe hepatic dysfunction. 
When first tested his blood showed antibody to hepatitis B surface 
antigen (anti-HBs), although no definite history of acute hepatitis 
could be obtained. A biopsy diagnosis of CAH was made in 1973; 
variceal bleeding became evident in 1976; and he underwent a 
splenectomy and a side-to-side portacaval shunt. In 1977 he had an 
appendectomy for a perforated appendix and in 1979 a cholecystec-
tomy for cholelithiasis. During the last 6 years of his life he had 
frequent episodes of hepatic encephalopathy in addition to hemophil-
ia-associated symptoms such as intramuscular (1M) hematomata 
and hemarthroses. Preoperative laboratory tests are shown in Tables 
I through 3. After a thorough evaluation the patient was accepted 
for transplantation; a donor liver became available approximately 6 
weeks later; and the procedure was performed on May 13, 1982. 
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F VIII:C (range 0.96 to 1.50 U/mL) within six hours after 
reestablishment of circulation through the new liver. His 
postoperative course was complicated by numerous infec-
tions. and he died with sepsis and an acquired immunodefi-
ciency-like syndrome 4 months after transplantation. The 
fourth patient was a 47-year-old mild hemophiliac with 
CAH who produced adequate factor VIII:C levels following 
transplantation (range 0.79 to 2.80 U/mL). These patients 
demonstrate that liver transplantation in hemophiliacs 
with end-stage liver disease may be lifesaving and results 
in correction of the F VIII:C deficiency and associated 
hemorrhagic tendency. 
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Intraoperatively he utilized 15,950 units of F VIn concentrate. The 
technical aspects of the transplant were greatly complicated by 
foreshortened recipient vessels, a result of previous operations, which 
made the construction of vascular anastomoses difficult. Venovenous 
bypass during the an hepatic phase, which decompresses the portal 
circulation, was not being used at that time. When the portal and 
caval venous circulations were occluded, the intestines became 
edematous, and uncontrollable bleeding ensued. A total of 55 units 
of RBCs and 61 units of fresh frozen plasma were transfused, but the 
patient died on the operating table. 
Patient 2 is a 16-year-old white, severely F VIII:C-deficient 
hemophiliac who had been treated with F VIn concentrate since 
early childhood. During the first year of life he had severe hepatitis 
B, which he transmitted to both parents. Subsequently hepatitis B 
surface antigen (HBsAg), anticore antibody (anti-HBc), and anti-
body to hepatitis B e antigen (anti-HBe) persisted. Additional 
laboratory tests are shown in Tables I through 3. In February 1984 
he developed liver enzyme elevations that may have represented 
non-A, non-B (NAN B) hepatitis or possibly a concurrent delta 
agent infection. In October 1984 he developed severe thrombocyto-
penia, which resolved following splenectomy. A simultaneous liver 
biopsy showed CAH. Postoperatively he developed a pancreatogas-
trocutaneous fistula that persisted for several months. Liver trans-
plantation and repair of the fistula were performed on March 5, 
1985. There was a small accumulation of ascites, but little difficulty 
was encountered during the transplant procedure, which required 
only four units of RBCs. The fistula repair included excision of 
numerous sinus tracts and required eight units of RBCs. During the 
operative and immediate postoperative period he was given 14,160 
units of heat-treated F VIn concentrate. Eighteen hours postopera-
tively F VIII infusions were discontinued, and the F VIII:C levels 
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Table 1. Coagulation Studies 
Patient 1 Patient 2 Patient 3 Patient 4 
3/5/85" 3/5/85;" 10/19/85;" 6/30/86;" 
3/8/85 t 2/14/85; 3/25/85t 10/9/85; 10/28/85t 6/17/86; 7/9/86t 
Test Normal Range 
Prothrombin time (s) 10-13 16.6 10.9 11.1 14.4 11.3 14.0 12.6 
Activated partial thromboplastin 
time (s) 24-34 107.0 39.0 31.9 53.9 29.8 60.7 46.8 
13-18 40.4 30.5 13.0 27.5 17.3 20.7 22.0 
13-18 50.4 35.1 33.6 29.9 
Thrombin time (s) 
Reptilase time (s) 
Euglobulin lysis time (min) 
Ethanol gel (0-4) 
Protamine gel (0-4) 
Wellcotest (j.lg/mL) 
120 or > 90 240 240 15 150 90 210 
0 0 2 1 0 0 0 
0 0 2 0 0 1 0 
0 0 >40 >10<40 >40 0 0 
1-4 0 0 8 128 0 0 0 Staph clumping titer 
Platelet count (103/ j.lL) 150-450 73 344 414 130 183 50 130 
* Date of surgery. 
tDates of tests. 
thereafter remained normal or supranormal. On the ninth postopera-
tive day he underwent revision of the bile duct reconstruction 
(initially performed during the transplantation), and on the 28th 
postoperative day a subphrenic abscess was drained. Both proce-
dures were performed without F VIII replacement therapy, and no 
excess bleeding was encountered. Pre-operative and postoperative 
coagulation findings are shown in Tables I and 2. 
Six weeks postoperatively he was discharged, and since that time 
he has maintained F VIII:C levels of 0.89 to 3.20 U jmL. He was 
given 20 vials (100 mL) of hepatitis B immune globulin (HBIG) 
intraoperatively and postoperatively. His HBsAg has remained 
positive except for several weeks (beginning about five weeks 
postoperatively) when it was negative and anti-Hbs appeared. Since 
then he has remained positive for HbsAg, anti- Hbs, and the antibody 
to delta agent. He returned to temporary employment in the summer 
of 1985 and returned to school in the fall of 1985. 
Patient 3 was a moderately obese, 48-year-old white, severely F 
VIII:C-deficient hemophiliac on home treatment with F V III con-
centrate as needed since 1973. Since that time his bilirubin, SGPT 
(AL T), and SGOT (AST) had been intermittently elevated and his 
anti-HBs had been positive. The patient had a strong history of 
alcohol abuse in the past but discontinued its use in 1974. Liver 
biopsy in 1976 showed portal fibrosis with fatty changes and early 
nodule formation. His liver disease was moderately stable until July 
of 1985 when there was a marked increase in girth due to develop-
ment of massive ascites. The spleen was enlarged; the gallbladder 
was contracted and contained gallstones. Subsequent progressive 
jaundice, malaise, accumulation of ascites, and poor response to 
diuretics heralded further clinical deterioration. Pre-operative and 
postoperative laboratory findings are shown in Tables 1 through 3. 
The patient was evaluated favorably for liver transplantation, and 
the procedure was performed on October 19, 1985. Twelve liters of 
ascitic fluid were removed. He received 17,290 units of heat-treated 
F VIn concentrate and ten units of RBCs intraoperatively. Postop-
eratively the patient received no F VIII concentrate, and his factor 
VIII:C level ranged from 0.96 to 1.50 UjmL. An episode of 
postoperative bleeding of unknown cause necessitated a repeat 
laparotomy. No excessive operative bleeding was encountered, and 
no F VIII concentrate was required. The patient suffered a mild 
rejection crisis and was successfully treated with OKT3 (Ortho 
Pharmaceuticals, Raritan, NJ) monoclonal antibody (MoAb) thera-
py. The rejection crisis was followed by pneumocystis carinii pneu-
Table 2. Coagulation Factor Assays (Pre- and Post-Liver Transplant) 
Patient 1 Patient 2 Patient 3 Patient 4 
Factor Pre Pre Post Pre Post Pre Post 
3/03/82 8/27/84 3/19/85 3/11/81 11/1/85 6/17 /86 7/15/86 
VIII:C) 0.02t O.Olt 1.75 t O.Olt 1. 15 t O. lOt 2.80 t 
vwF U/mL* 10.0 6.24 3.68 1.06 6.24 2.32 3.36 
RCF 4.35 3.75 4.64 0.97 4.20 3.40 2.76 
5/13/82 2/14/85 3/25/85 10/09/85 10/28/85 6/17/36 7/9/86 
mg/dL 180 375 420 240 270 160 440 
0.3 0.78 0.90 0.48 0.70 0.46 0.80 
V 0.57 0.80 0.96 0.36 1.25 0.22 0.44 
VII 0.18 0.68 0.66 0.23 0.60 0.35 0.58 
VIII;C 0.11:1: 1.30:1: 1.20t 0.33:1: l.4°t O. lOt 1. 10t 
IX U/mL* 0.11 0.95 1.00 0.26 0.86 0.48 0.90 
X 0.49 0.80 1.05 0.68 0.58 0.56 1.05 
XI 0.15 0.39 0.63 0.24 0.52 0.19 0.55 
XII 0.36 0.91 0.66 0.67 0.78 0.43 0.63 
*Normal range, 0.5 to 1.5 U/mL. 
t Not treated with F VIII. 
tT reated with F VIII. 
LIVER TRANSPLANTATION IN HEMOPHILIA A 
Table 3. Preoperative Hepatitis Serologies. Liver Function Tests. 
and Anti-HIV Results 
Test Patient 1 Patient 2 Patient 3 Patient 4 
HBsAg 0 + 0 0 
HBeAg ND ND ND 
Anti-HBe ND + ND ND 
Anti-delta ND + ND ND 
Anti-HBs + 0 + + 
Anti-HBc + + + + 
Bilirubin (mg%): 
Total 5.0 3.5 25.1 3.0 
Direct 3.0 1.4 12.7 0.9 
SGOT (AST) (IU) 202 313 120 48 
SGPT (AL T) OU) 80 79 62 26 
Anti-HIV ELISA + + + 
Western blot + + + ND 
ND, not done. 
monia, which resolved with trimethoprim-sulfamethoxazole therapy. 
Subsequently a cytomegalovirus infection resolved without treat-
ment. Four mon ths postoperatively he developed Escherichia coli 
and pseudomonas sepsis, to which he succumbed despite parenteral 
antibiotics and intensive care. 
Patient 4 is a 47-year-old mildly F VIII:C-deficient hemophiliac 
who had a F Vlll:C level of 0.10 U/mL and a history of CAH 
secondary to NAN B hepatitis accompanied by episodes of variceal 
bleeding, encephalopathy, and cholecystitis. Liver transplantation 
was performed on June 30, 1986 with 17,120 units of heat-treated F 
VIII concentrate and eight units of RBCs transfused intraoperative-
ly. Preoperative and postoperative coagulation findings are shown in 
Tables I and 2. No factor VIII replacement was given postopera-
tively, and the new liver began synthesizing F VIII:C within four 
hours after the procedure. His postoperative course was complicated 
by a mild rejection episode, which was also treated successfully with 
OKT3 MoAb, and the patient was discharged approximately 8 
weeks postoperatively after maintaining F VIII:C levels between 
0.79 and 2.80 U/mL. 
DISCUSSION 
Successful liver transplantation in the hemophiliacs pre-
sented here not only reversed the hepatic failure but also 
corrected the coagulation defect of hemophilia A. These 
results demonstrate that hemophilia should not be a con-
traindication for the procedure and that resolution of the 
hemophilia, except for genetic transmissibility, should be 
expected. Therefore consideration of this procedure as a 
feasible, albeit difficult option should be given to the small 
but significant number of hemophiliacs who suffer from 
end-stage liver disease. The fatal outcome of Patient 1 
suggests that scarring and fibrous changes after abdominal 
surgical procedures, especially shunting procedures and 
splenectomy, may make liver transplantation difficult or 
impossible and should be avoided. Whether or not the 
presence of human immunodeficiency virus (HIV) antibod-
ies in a transplant candidate will alter the selection process 
remains to be determined. Three of these four patients were 
HIV antibody positive, and one of the three suffered from 
opportunistic infections typical of acquired immunodefi-
ciency syndrome (AIDS) or the immunosuppressed post-
transplantation state. 17 The diagnostic criteria of the Centers 
for Disease Control (CDC), however, exclude the diagnosis 
of AIDS in patients receiving immunosuppressive agents. At 
1723 
this point exclusion of anti-HIV-positive hemophiliacs for 
liver transplant consideration seems to be premature. 
Although liver transplantation with its attendant risks and 
requirements for lifelong immunosuppression cannot be rec-
ommended as a treatment for hemophilia per se, it clearly 
may avert imminent death in hemophiliacs with end-stage 
liver disease and also appears to cure the coagulation defect. 
Future prospects for the availability of recombinant F 
VIIl:C products may decrease the present high risk of 
transmissible liver disease's and eventually obviate the need 
for liver transplantation in hemophilia. 
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